REGENXBIO/$RGNX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About REGENXBIO
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Ticker
$RGNX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
353
ISIN
US75901B1070
Website
REGENXBIO Metrics
BasicAdvanced
$434M
-
-$3.10
1.11
-
Price and volume
Market cap
$434M
Beta
1.11
52-week high
$15.36
52-week low
$5.04
Average daily volume
1.1M
Financial strength
Current ratio
2.935
Quick ratio
2.821
Long term debt to equity
30.279
Total debt to equity
48.697
Interest coverage (TTM)
-8.17%
Profitability
EBITDA (TTM)
-141.366
Gross margin (TTM)
80.24%
Net profit margin (TTM)
-100.62%
Operating margin (TTM)
-100.41%
Revenue per employee (TTM)
$440,000
Management effectiveness
Return on assets (TTM)
-17.56%
Return on equity (TTM)
-47.44%
Valuation
Price to revenue (TTM)
2.801
Price to book
1.58
Price to tangible book (TTM)
1.58
Price to free cash flow (TTM)
-5.048
Free cash flow yield (TTM)
-19.81%
Free cash flow per share (TTM)
-170.76%
Growth
Revenue change (TTM)
80.70%
Earnings per share change (TTM)
-47.21%
3-year revenue growth (CAGR)
-30.84%
10-year revenue growth (CAGR)
44.95%
3-year earnings per share growth (CAGR)
10.62%
10-year earnings per share growth (CAGR)
0.85%
What the Analysts think about REGENXBIO
Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.
Bulls say / Bears say
REGENXBIO's submission of a Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) positions the company for potential FDA approval in the second half of 2025, marking a significant milestone in their gene therapy pipeline. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
The strategic partnership with Nippon Shinyaku, which includes a $110 million upfront payment and up to $700 million in milestone payments, significantly strengthens REGENXBIO's financial position and commercial prospects. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
Positive interim biomarker data from the AFFINITY DUCHENNE® trial of RGX-202 gene therapy for Duchenne Muscular Dystrophy indicates favorable safety and efficacy, supporting the potential for accelerated development timelines. (REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY)
REGENXBIO reported a net loss of $227.1 million for the year ended December 31, 2024, indicating ongoing financial challenges despite revenue streams. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
The company's revenue decreased to $83.3 million in 2024 from $90.2 million in 2023, primarily due to a decline in Zolgensma royalty revenues, which could impact financial stability. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
Despite a strong cash position, the company's cash, cash equivalents, and marketable securities decreased to $244.9 million as of December 31, 2024, from $314.1 million the previous year, reflecting increased cash burn. (REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
REGENXBIO Financial Performance
Revenues and expenses
REGENXBIO Earnings Performance
Company profitability
REGENXBIO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for REGENXBIO stock?
REGENXBIO (RGNX) has a market cap of $434M as of July 04, 2025.
What is the P/E ratio for REGENXBIO stock?
The price to earnings (P/E) ratio for REGENXBIO (RGNX) stock is 0 as of July 04, 2025.
Does REGENXBIO stock pay dividends?
No, REGENXBIO (RGNX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next REGENXBIO dividend payment date?
REGENXBIO (RGNX) stock does not pay dividends to its shareholders.
What is the beta indicator for REGENXBIO?
REGENXBIO (RGNX) has a beta rating of 1.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.